WuXi AppTec

Global Aging And Advanced Therapies Will Expand Outsourcing

AnalystHighTarget

Not Invested

Community Contributor

Published

03 Aug 25

AnalystHighTarget's Fair Value

CN¥138.00

30.0% undervalued

10 Sep

CN¥96.60

92.4%

-7.8%

92.4%

-7.8%

You can edit this narrative until Aug 3 9:22 PM. Then, changes will post as Updates.

Author's Valuation

CN¥13830.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CN¥138

30.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

11.56%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.46%

Calculation

CN¥21.70b

Earnings '28

33.09x

PE Ratio '28

CN¥717.99b

Market Cap '28

CN¥717.99b

Market Cap '28

4.20b

No. shares '28

CN¥170.80

Share Price '28

CN¥170.80 Share Price '28

Discounted to 2025 @ 7.37% p.a.

CN¥138.00

Fair Value '25